Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Blood (2024) 144 (Supplement 1): 568.

https://doi.org/10.1182/blood-2024-207946

Published: 2024

Journal Articles

MDS-AML Aggregative Risk Classification System ( MARCS ): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Marco Roncador, Fritz Bayer, Jeremy W. Deuel, Jack Kuipers, Markus G. Manz, Steffen Boettcher, Niko Beerenwinkel, Stefan Balabanov

Blood (2024) 144 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2024-203134

Published: 2024

Journal Articles

Multiomics Profiling Reveals Higher RNA Isoform Diversity and Potential Oncospecific Protein Isoform Targets in HSPCs of MDS and MDS/MPN Patients

Nicolas Bonadies, Vladislav Grigorjev, Naomi Porret, Keith Harshman, Linda L Grob, Tata Nageswara Rao, Lina Al Tai, Rosanna Rubin, Helen Broughton, Sandra Goetze, Nora C Toussaint, Stefan Balabanov

Blood (2023) 142 (Supplement 1): 4592.

https://doi.org/10.1182/blood-2023-178092

Published: 2023

Journal Articles

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Martin Kirschner, MD, Monica Sofia Ventura Ferreira, PhD, Anne-Sophie Bouillon, MD, Marcin W. Wlodarski, MD PhD, Michaela Schwarz, MD, Stefan Balabanov, MD PhD, Stefan Wilop, MD, Steffen Koschmieder, MD, Jens P. Panse, MD, Tim H. Brümmendorf, MD, Fabian Beier, MD

Blood (2018) 132 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2018-99-118197

Published: 2018

Journal Articles

BCR-ABL Cooperates With a “Telomere-Associated Secretory Phenotype” (TASP) To Facilitate Malignant Proliferation Of Hematopoietic Stem Cells

Tim H. Brümmendorf, MD, Nora Pällmann, Michael Preukschas, Doris Steinemann, PD Dr. rer. nat., Winfried Hofmann, Dr. rer. nat., Anne Gompf, Karl L. Rudolph, Carsten Bokemeyer, MD, Steffen Koschmieder, Andreas Schuppert, Stefan Balabanov, Melanie Braig

Blood (2013) 122 (21): 3976.

https://doi.org/10.1182/blood.V122.21.3976.3976

Published: 2013

Journal Articles

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Blood (2012) 120 (21): 302.

https://doi.org/10.1182/blood.V120.21.302.302

Published: 2012

Journal Articles

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Tim H Brümmendorf, Patrick Ziegler, PhD, Jamil Akkad, MD, Ute Brassat, PhD, Lucia Vankann, Jens Panse, MD, Stefan Wilop, MD, Stefan Balabanov, MD, PhD, Klaus Schwarz, MD, Uwe M. Martens, MD, PhD, Hubert Schrezenmeier, MD

Blood (2011) 118 (21): 3427.

https://doi.org/10.1182/blood.V118.21.3427.3427

Published: 2011

Journal Articles

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Tim H Brummendorf, MD, Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost, Oliver Galm, Carsten Bokemeyer, MD, Tessa Holyoake, Stefan Balabanov

Blood (2009) 114 (22): 1724.

https://doi.org/10.1182/blood.V114.22.1724.1724

Published: 2009

Journal Articles

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Stefan Balabanov, MD/PhD, Artur Gontarewicz, MD, Gunhild Keller, MD, Jürgen Moll, PhD, Carsten Bokemeyer, MD, Tessa L Holyoake, MD/PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 3227.

https://doi.org/10.1182/blood.V112.11.3227.3227

Published: 2008

Journal Articles

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Stefan Balabanov, MD/PhD, Thoma Wilhelm, PhD, Simone Venz, PhD, Christine Barret, Gunhild Keller, MD, Mirja Bernhardt, Artur Gontarewicz, MD, Melanie Braig, PhD, Reinhard Walther, PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 336.

https://doi.org/10.1182/blood.V112.11.336.336

Published: 2008

Journal Articles

Functional p53 Is Required for Effective Telomerase Inhibition in BCRABL- Positive CML Cells in Vitro

Ute Brassat, Stefan Balabanov, Melanie Braig, Daniel Bali, Kerstin Borgmann, Tim H. Brummendorf

Blood (2008) 112 (11): 572.

https://doi.org/10.1182/blood.V112.11.572.572

Published: 2008

Journal Articles

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Artur Gontarewicz, Stefan Balabanov, Gunhild Keller, Riccardo Colombo, Alessio Graziano, Enrico Pesenti, Daniel Benten, Carsten Bokemeyer, Walter Fiedler, Jürgen Moll, Tim H. Brümmendorf

Blood (2008) 111 (8): 4355–4364.

https://doi.org/10.1182/blood-2007-09-113175

Published: 2008

Journal Articles

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D., Gunhild Keller, M.D., Riccardo Colombo, Ph.D., Alessio Graziano, Ph.D, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.

Blood (2007) 110 (11): 1042.

https://doi.org/10.1182/blood.V110.11.1042.1042

Published: 2007

Journal Articles

Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.

Ute Brassat, Stefan Balabanov, M.D., Ph.D., Henning Wege, M.D., Daniel Roessler, Kerstin Borgmann, M.D., Tim Brummendorf, MD

Blood (2007) 110 (11): 2935.

https://doi.org/10.1182/blood.V110.11.2935.2935

Published: 2007

Journal Articles

PHA-680626 Exhibits Anti-Proliferative and Pro-Apoptotic Activity on Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines and Primary CD34+ Cells by Inhibition of Both Bcr-Abl Tyrosine Kinase and Aurora Kinases.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D, Gunhild Keller, M.D., Jens Panse, M.D., Mirja Bernhardt, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.

Blood (2007) 110 (11): 4568.

https://doi.org/10.1182/blood.V110.11.4568.4568

Published: 2007

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Ute Brassat, Stefan Balabanov, MD/PhD, Ulrike Hartmann, PhD, Daniel Rössler, Kerstin Borgmann, PhD, Judith Dierlamm, MD/PhD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 2185.

https://doi.org/10.1182/blood.V108.11.2185.2185

Published: 2006

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD

Blood (2005) 106 (11): 1997.

https://doi.org/10.1182/blood.V106.11.1997.1997

Published: 2005

Journal Articles

Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)–negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH

Fabian Beier, Stefan Balabanov, Tom Buckley, Klaus Dietz, Ulrike Hartmann, Markus Rojewski, Lothar Kanz, Hubert Schrezenmeier, Tim H. Brümmendorf

Blood (2005) 106 (2): 531–533.

https://doi.org/10.1182/blood-2004-10-3996

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

MDS-AML Aggregative Risk Classification System ( MARCS ): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Multiomics Profiling Reveals Higher RNA Isoform Diversity and Potential Oncospecific Protein Isoform Targets in HSPCs of MDS and MDS/MPN Patients

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

BCR-ABL Cooperates With a “Telomere-Associated Secretory Phenotype” (TASP) To Facilitate Malignant Proliferation Of Hematopoietic Stem Cells

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Functional p53 Is Required for Effective Telomerase Inhibition in BCRABL- Positive CML Cells in Vitro

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.

PHA-680626 Exhibits Anti-Proliferative and Pro-Apoptotic Activity on Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines and Primary CD34+ Cells by Inhibition of Both Bcr-Abl Tyrosine Kinase and Aurora Kinases.

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)–negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only